Search

Introduction: Diabetic peripheral neuropathy (DPN), a prevalent complication among individuals diagnosed with type 2 diabetes, has a significant impact on both the well-being of patients and their financial situation. Acupuncture has been employed for thousands of years within China and is regarded as one of the primary characteristic therapies of traditional Chinese medicine. Research has indicated that acupuncture has the potential to enhance microcirculation, decrease the generation of free radicals, and augment nerve conduction velocity. There had been several meta-analyses of acupuncture on DPN. Nevertheless, there has been inadequate attention given to the assessment of blood glucose control, and scores related to quality of life. Hence, we get additional evidence by enhancing the quantity and quality of studies to draw more distinct findings. Methods: We will conduct a comprehensive search for reports published from the beginning until June 2023 using various databases including Web of Science, Embase, Cochrane Library, PubMed, AMED, Wanfang database, VIP database, China National Knowledge Infrastructure, and Chinese Biomedical Literature database. Only randomized controlled trials will be considered, with no exclusion of quasi-randomized control trials. Articles in both English and Chinese will be taken into account without any limitations on publication dates. The data will be extracted, managed, and analyzed by two researchers working independently. The primary outcomes will include improvement of symptom scores, change of nerve conduction velocity, and quality of life scores. Additional outcomes will encompass blood glucose levels after fasting and 2 hours after eating, levels of glycosylated hemoglobin, and any adverse events associated with acupuncture. We plan to use the RevMan V.5.4 application and the random-effects model for conducting the meta-analysis. The assessment of potential prejudice can be conducted by Cochrane's 'risk of bias' 2 (RoB 2) tool. Registration: PROSPERO (registration number: CRD42023425203). Discussion: Our goal is to perform a meta-analysis that offers an unbiased approach to treating individuals with type 2 DPN. At the same time, it also provides doctors with more choices in the treatment of diabetes peripheral neuropathy. [ABSTRACT FROM AUTHOR]

Aiming at the problem of low specific capacitance of activated carbon, utilizing the large specific surface area and abundant pore structure of metal organic frameworks (MOFs), a synergistic bilayer mechanism with pseudocapacitive properties of MOFs-derived porous carbon hybrid composites with activated carbon was investigated in this paper. N-doped porous carbon composites were prepared by designing different Zn/Co ratios and carbonization temperatures. ZCPC@AC-800 was tested in a three-electrode system and showed a specific capacitance of 327.5 F/g at 0.5 A/g, which was higher than that of the MOF-derived porous carbon composites generated from monometallic atoms, due to the fact that the bimetallic MOFs in the nanocomposites could provide a more diverse range of active sites during pyrolysis. In addition, symmetric supercapacitors (ZCPC@AC-800||ZCPC@AC-800) assembled in a 3 mol/L KOH electrolyte with a potential window of 0-1.5 V have an energy density of 21 Wh/kg at a power density of 375 W/kg. After cycling test, its initial specific capacitance remained 80% after 5 000 times of charging and discharging at 5 A/g. [ABSTRACT FROM AUTHOR]

On account of their excellent properties, such as high surface area, non-toxicity, high porosity, and biocompatibility towards bodily fluids, calcium carbonate (CaCO3) nano particles have a good deal of industrial applications. Here, the present study reports a facile strategy combined with a ball milling process and a subsequent hydrothermal treatment to synthesize CaCO3 nano powders. Homogeneous CaCO3 precursors with an average size of 80 nm were prepared via a ball milling process, which subsequently transformed as well crystallized CaCO3 nano powders with an average size of 145 nm after the hydrothermal condition at 160 ℃ for 12 h. The as-obtained CaCO3 nano powders demonstrated good homogeneity with narrow size distribution and improved dispersibility, suggesting they are compatible in current industrial applications. [ABSTRACT FROM AUTHOR]

Introduction: Diabetic peripheral neuropathy (DPN), a widely prevalent complication in patients with type 2 diabetes, exerts a significant influence on patients' overall health and financial circumstances. Photobiomodulation therapy is one of the means of physical therapy for DPN. Although preliminary findings suggest the efficacy of photobiomodulation therapy in alleviating peripheral neuropathy, the existing literature lacks substantial evidence regarding its safety and effectiveness specifically in the context of diabetes-related peripheral neuropathy. Therefore, we plan to arrive at more distinct findings through systematic evaluation and meta-analysis. Methods: We will conduct a comprehensive search for studies published from the beginning until October 1, 2023, using various databases including Web of Science, Embase, Cochrane Library, PubMed, AMED, Wanfang database, VIP database, China National Knowledge Infrastructure, and the Chinese Biomedical Literature database. Simultaneously, we will also search for the WHO International Clinical Trial Registration Platform, China Clinical Trial Registration Platform, and Clinical Trials.gov. Gray literature will be retrieved using Google Scholar and opengrey.edu. Only randomized controlled trials in Chinese and English were included, with no restrictions on publication status. The primary outcomes will include change of symptom scores, change of nerve conduction velocity. Additional outcomes will encompass quality of life, change in pain, blood glucose levels after fasting and 2 hours after eating, levels of glycosylated hemoglobin, and any adverse events associated with photobiomodulation therapy. Reman V.5.4 and R language will be used for the meta-analysis. Assessment of potential bias will be conducted through Cochrane risk of bias 2 tool (RoB 2.0) and Physiotherapy Evidence Database (PEDro) scale. Registration: PROSPERO (registration number: CRD42023466586). Discussion: This meta-analysis aims to assess the efficacy and safety of photobiomodulation therapy as a potential treatment for diabetic peripheral neuropathy (DPN), and providing a straightforward and convenient therapeutic for patients. Additionally, it expands the range of treatment alternatives available to healthcare professionals managing DPN. [ABSTRACT FROM AUTHOR]